Ddx5 Targeted Epigenetic Modification of Pericytes in Pulmonary Hypertension After Intrauterine Growth Restriction

Chengcheng Hang1, Lu Zu1, Xiaofei Luo2

  • 1Department of Neonatology and.

Insights

Newborns with intrauterine growth restriction (IUGR) may develop pulmonary arterial hypertension (PAH). A study found that targeting the miR-205/Ddx5 pathway could treat IUGR-related PAH by improving pericyte function.

Area of Science:

  • Cardiovascular Research
  • Pulmonary Medicine
  • Molecular Biology

Background:

  • Intrauterine growth restriction (IUGR) increases the risk of adult pulmonary arterial hypertension (PAH).
  • Pericytes are implicated in cardiovascular diseases, but their role in IUGR-related PAH is unclear.
  • Understanding the mechanisms of IUGR-related PAH is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of pericytes in IUGR-related pulmonary hypertension.
  • To identify molecular mechanisms underlying pericyte dysfunction in this condition.
  • To explore potential therapeutic targets for IUGR-related PAH.

Main Methods:

  • Utilized a Sprague-Dawley rat model of IUGR-related pulmonary hypertension.
  • Conducted whole-transcriptome sequencing to identify key genes in pericytes.
  • Performed dual-luciferase reporter assays to confirm microRNA-gene interactions.
  • Conducted in vitro and in vivo experiments to assess therapeutic interventions.

Main Results:

  • Pulmonary microvascular pericytes showed increased proliferation and migration in IUGR-related pulmonary hypertension.
  • Ddx5 was identified as a hub gene in pericytes, regulated by miR-205.
  • miR-205 ameliorated pericyte dysfunction and pulmonary hypertension in vivo.
  • Downregulation of miR-205 activates Ddx5, leading to pericyte dysfunction.

Conclusions:

  • The miR-205/Ddx5/p-Gsk3β/β-catenin axis is a key pathway in IUGR-related pulmonary hypertension.
  • miR-205 downregulation mediates pericyte dysfunction via Ddx5 activation.
  • Targeting this axis offers a potential therapeutic strategy for IUGR-related PAH.